CCCardiol CroatCardiologia CroaticaCardiol. Croat.1848-543X1848-5448Croatian Cardiac SocietyCC 2024 19_11-12_40710.15836/ccar2024.407Extended AbstractArrhythmology and electrostimulationSurvival benefits of an implantable cardioverter-defibrillator implantation: comparing outcomes in ischemic and non-ischemic cardiomyopathy – single centre experiencehttps://orcid.org/0000-0003-1477-2581PuljevićMislav12*https://orcid.org/0000-0003-0441-4772Dubravčić DošenMia2https://orcid.org/0000-0002-6587-2315PašaraVedran2https://orcid.org/0000-0001-5870-202XPrepolecIvan2https://orcid.org/0000-0001-7382-4789HrabačPero1https://orcid.org/0000-0003-0053-0442BrekaloAna-Marija2https://orcid.org/0000-0001-8446-6120Lovrić-BenčićMartina12https://orcid.org/0000-0002-0639-953XKrpanMiroslav2https://orcid.org/0000-0003-1289-1704MatasićRichard2https://orcid.org/0000-0002-0504-5238Pezo NikolićBorka2https://orcid.org/0000-0003-3603-2242PuljevićDavor12https://orcid.org/0000-0001-9101-1570MiličićDavor12https://orcid.org/0000-0001-5425-5840VelagićVedran12University of Zagreb, School of Medicine, Zagreb, CroatiaUniversity Hospital Centre Zagreb, Zagreb, CroatiaADDRESS FOR CORRESPONDENCE: Mislav Puljević, Klinički bolnički centar Zagreb, Kišpatićeva 12, HR-10000 Zagreb, Croatia. / Phone: +385-91-4680-414 / E-mail: puljevicmislav@gmail.com1120241120241911-124074072409202431102024Croatian Cardiac Society2024Croatian Cardiac SocietyKEYWORDS: implantable cardioverter-defibrillatorsudden cardiac deathnon-ischemic cardiomyopathyischemic cardiomyopathy
Introduction: While implantable cardioverter-defibrillators (ICD) effectively reduce sudden cardiac death, their impact on overall survival differs between ischemic cardiomyopathy (ICM) and non-ischemic cardiomyopathy (NICM). (1-3) This study investigates survival outcomes and the significance of age in a cohort of ICD recipients.
Patients and Methods: A retrospective cohort of 786 patients who underwent ICD implantation between 2009 and 2018 was analyzed. Survival outcomes were assessed with a focus on differences between ICM and NICM, and the influence of age on device efficacy.
Results: Patients with NICM showed a lower rate of appropriate device activation compared to ICM (23% vs. 28%). Despite this, ICD implantation significantly improved survival in both groups, with younger patients (<70 years) benefiting the most. Age, non-sustained ventricular tachycardia (NSVT), and cardiac decompensation history were strong predictors of (non)survival.
Conclusions: ICD implantation offers clear survival benefits in both ICM and NICM, though younger patients and those with ischemic cardiomyopathy experience better outcomes. Age and cardiomyopathy type are crucial factors in determining the effectiveness of ICD therapy.
LITERATURETheunsDAVerstraelenTEvan der LingenACJDelnoyPPAllaartCPvan ErvenLImplantable defibrillator therapy and mortality in patients with non-ischaemic dilated cardiomyopathy: An updated meta-analysis and effect on Dutch clinical practice by the Task Force of the Dutch Society of Cardiology.Neth Heart J. 2023 March;31(3):89–99. 10.1007/s12471-022-01718-336066840ElmingMBNielsenJCHaarboJVidebækLKorupESignorovitchJAge and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.Circulation. 2017 November 7;136(19):1772–80. 10.1161/CIRCULATIONAHA.117.02882928877914ZeppenfeldKTfelt-HansenJde RivaMWinkelBGBehrERBlomNAESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Eur Heart J. 2022 October 21;43(40):3997–4126. 10.1093/eurheartj/ehac26236017572